Corticosteroids represent the most important and frequently used class of anti-inflammatory and immunosuppressant agents in the management of many rheumatological conditions. Included in this issue will be articles on the following topics: Glucocorticoid use in intra-articular and soft tissue injections, corticosteroids and osteoporosis, corticosteroids in lupus, ANCA associated vasculitis, and many more!

Churchill's Pocketbook of Orthopaedics, Trauma and Rheumatology offers a practical guide to these three combined disciplines in a handy pocketbook format and is ideal for medical students, junior doctors and trainees. The book is perfect for clinical placements in orthopaedics, emergency medicine, rheumatology and general practice, as well as during the undergraduate musculoskeletal anatomy course. The book guides the reader through effective history taking, patient examination, and the selection and interpretation of routine investigations. There are sections on anatomy, paediatrics and trauma assessment, including pre- and post-operative care and complications, together with a comprehensive section on the common medications used in all three specialties. The book will help improve a reader's diagnostic skills and inform about current treatment options In this second edition the authors have updated the content to reflect changes in surgical practice and advances in therapeutics, as well as the molecular understanding of genetic and inflammatory disorders. Details of common procedures have been added. The updated layout has new 'overview' and 'hints and tips' boxes. The aim of the revision has been to provide concise and important information to both medical students revising for their exams, but also to junior doctors in their first years following graduation.

Some people with psoriasis can also develop psoriatic arthritis, when the immune system attacks the joints as well, causing inflammation. Like psoriasis, psoriatic arthritis symptoms flare and subside, vary from person to person, and even change locations in the same person over time. Psoriatic arthritis can affect any joint in the body, and it may affect just one joint, several joints or multiple joints. For example, it may affect one or both knees. This issue will include articles on Genetic and Epigenetic aspects of psoriatic arthritis, Clinical features and diagnostic considerations in psoriatic arthritis, Natural history, prognosis and socioeconomic aspects of psoriatic arthritis, Etiology and pathogenesis of psoriasis and many more!

Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. Hardening of the skin is one of the most visible manifestations of the disease. It's estimated that about 300,000 Americans have scleroderma. About one third of those people have the systemic form of scleroderma. Since scleroderma presents with symptoms similar to other autoimmune diseases, diagnosis is difficult. This issue will cover: The Genetic Basis of SSc: Genetics, Epigenetics, Mechanisms of Pathogenesis - linking fibrosis, vasculopathy and immune dysregulation, The Role of Autoantibodies in Diagnosis and Prognosis/survival, Managing Raynaud's phenomenon and ischemic ulcers Managing SSc Lung Disease, Monitoring for and Managing Pulmonary Arterial Hypertension, and many more!

The lungs are involved so frequently with rheumatologic problems. This issue will cover Radiology of lung disease in the rheumatic diseases, Histopathology of lung disease in the rheumatic diseases, Determining respiratory impairment, Lung disease in RA, Lung disease in scleroderma, and many more!

Malpractice settlements are large for undetected hydroxychloroquine and chloroquine toxicity which, if untreated, can lead to permanent loss of central vision. Knowledge of the ocular toxicity of these drugs has increased during the past fifty years as their use has expanded. Hydroxychloroquine and Chloroquine Retinopathy is the first single-source book on the subject and is essential for the practicing ophthalmologists, rheumatologists, dermatologists, and internists who prescribe these drugs. It covers clinical topics such as signs and symptoms of toxicity, toxicity screening, ancillary testing, to whom and why the drugs are prescribed and dosing considerations. Additionally, the book addresses practice management considerations, including coding, reimbursement and equipment costs, and the medico-legal responsibilities of the rheumatologist and of the ophthalmologist. Guidelines for the management of hydroxychloroquine and chloroquine vary around the world and differences between the guidelines of the United Kingdom, the United States, and other countries are identified. The book concludes with a collection of case examples illustrating common clinical scenarios and their management. This book is a "must-have" resource for physicians who use these drugs.

The ability to intervene at the earliest phases in the pathogenesis of a chronic rheumatic disease caused by auto-inflammatory, autoimmune, or tissue injury mechanisms has th epotential to prevent disease manifestations and consequences, limited loss of quality of life, comorbidity, and costs to society. This issue is dedicated to exploring the stages of rheumatic disease, biologic mechanisms contributing to the pathogenesis along with possible ways to study and screen for persons at risk with the ultimate goal of finding ways to prevent these devastating diseases.

This issue brings the rheumatologist on the current thinking on treatment of Systemic Lupus Erythematosus, with an eye to the future. Topics covered include B cell biology and related therapies; glutamate receptor biology and its clinical significance in neuropsychiatric SLE; platelet C4d and vascular complications; biomarkers in lupus nephritis; endothelial function and its implications for cardiovascular and renal disease in SLE; changing worldwide epidemiology of SLE and its relationship to environmental, ethnic, and other sociodemographic factors; work loss, disability, quality of life, and compliance in SLE; pediatric lupus; metabolic syndrome and related endocrine abnormalities; the significance of interferon and the consequences of anti-interferon in SLE; and cutaneous lupus and the CLASI instrument.

With the FDA release of the drug Uloric in 2009, the research and interest around gout and crystal arthropathies has exploded. Gout affects over 8 million Americans. The gout rate was 7% among Americans aged 60 to 79 in the early 1990s, compared with 9% by 2008. Among those aged 80 and older, the rate more than doubled, from 6% to 13% over the nearly 20-year time span. This topic has never been covered in Rheumatic Disease Clinics and it represents a large content hole. The articles will cover diagnosis, management, emerging therapies and imaging

Gout is now the most common form of inflammatory arthritis in the United States, with a recent resurgence of research interest in its cause and management. Calcium crystal-related arthritis has also attracted renewed attention, with new nomenclature having been recently elaborated, aiding contemporary research efforts. This topic has never been covered in Rheumatic Disease Clinics and it represents a large content hole. The articles will cover diagnosis, management, emerging therapies and imaging.

Congenital hip disease (CHD) is the main cause of secondary osteoarthritis (OA) of the hip in young adults, which accounts for almost 40% of all cases of hip OA. Total hip replacement (THR) performed using optimal techniques can achieve a radical improvement in the quality of life of adult patients. This book offers in-depth coverage of all aspects of CHD in adults and its treatment. Relevant information is first provided on the basic anatomy of the hip and OA of the hip and on the classification, epidemiology, and natural history of CHD. The now limited role of femoral and pelvic osteotomies is carefully evaluated, and the use of THR is then considered in detail. Indications and preoperative planning are discussed, and the available operative techniques, analyzed. Clear guidance is provided on overcoming major technical difficulties, and the benefits of particular approaches and techniques are highlighted. More than 180 images and numerous case studies complement this reader-friendly text. The book will be an invaluable tool for orthopedic surgeons, rheumatologists and radiologists.

Newly Diagnosed? Long Time Sufferer?

You are NOT alone You CAN change your life and REVERSE this highly frustrating, emotionally confusing, very often unrecognized "invisible" illness.

"A must-read, Chantal's book will bring you HOPE, INSIGHTFUL tips and POSITIVE results. This AMAZING book has changed my Fibromyalgia life." - Kris Bruinsma, FMS survivor

"I am so proud to read this book written by my friend, Chantal. Her articles have graced many publications including my own and I am thrilled that she has taken the time to make her story public. I know firsthand the power of shared experiences on recovery and know her book will make a difference to so many." -Claudia Marek, Co-author of What Your Doctor May Not Tell You about Fibromyalgia

"This is a story of hope and determination written by an individual who has been a patient in my integrative medical practice for the past eight years. She is an outspoken advocate and our resident expert in the protocol of Paul St. Amand, MD. She has graced us with her knowledge and exuberant energy at out clinic's monthly fibromyalgia support group meetings. She is the consummate teacher and is always available to help our other fibromyalgia patients working through the subtleties of the Guaifenesin Protocol.

A must-read for anyone lost in the abyss of fibromyalgia with seemingly no apparent way out."
-Thaddeus P. Srutwa, MD, Spring Lake, MI

Ibuprofen is one of the most successful drugs used worldwide for the treatment of mild to moderate pain and various inflammatory conditions. Over the past 40 years, ibuprofen has been proven to be as safe or even safer and also as effective as the established non-steroidal anti-inflammatory drugs (NSAIDs) and the coxibs. This well-written book reviews the pharmacology, clinical uses and the various adverse effects of Ibuprofen, the disposition and unique modes of action in relation to clinical effects of the drug as well as various formulations. The use of combinations with other drugs (e.g. paracetamol, codeine, caffeine) are critically assessed and the impact of natural products and Chinese Medicines on the safety of ibuprofen.

Guest edited by Jonathan Kay, this issue of Rheumatic Disease Clinics will cover the latest research and evidence surrounding the diagnosis, treatment and management of rarely seen rheumatic diseases.

This issue of Rheumatic Disease Clinics teaches you the latest best practices for using musculoskeletal ultrasound to diagnose and monitor the progression of rheumatoid arthritis, vasculitis, and other rheumatic and soft tissue disorders.

This book explores comorbidity in patients with rheumatic diseases and details both care and treatment options in standard clinical practice. Patients with rheumatic diseases are clinically complex, and the interplay of their disease activity with associated conditions may lead to increased morbidity and mortality. Recently there have been major advances in the management of rheumatic diseases, however, without addressing the potential comorbid conditions, including cardiovascular disease; pulmonary disease; and depression; outcomes remain poor. With its 19 chapters, covering the management of major rheumatic diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus , and osteoarthritis), potential comorbidities and treatment recommendations, as well as possible interactions between conditions; this book addresses the gap between textbook medicine and day to day patients' care. Authors also discuss the new hot issue of the comorbidity index, comparing the standard tools to the recently developed indices and how they can assist the rheumatologists in determining disease burden, prognosis, and comorbidity probability. This book is an ideal clinical guide and reference that enables rheumatologists, internal medicine physicians, and residents to address the full clinical expression of these rheumatic diseases with views towards prevention or early management of comorbid conditions.

Osteoarthritis is the leading cause of disability among older adults affecting upward of 1 in 8 adults. This issue will cover epidemiology, imaging, disease management and modification, and many more topics.

Edited by Drs. Jack Cush and Kathryn Dao, this issue of Rheumatic Disease Clinics of North America addresses one of the most significant issues facing the rheumatologist today--drug safety in a changing world where rheumatoid arthritis (RA) severity is less, patients are being identified and treated at a very early stage, and prevention is on the horizon. Topics covered include: communicating the risk of side effects, urate-lowering therapies, biphosphonates, biologics, malignancy risks, and administering therapies to patients with co-morbidities.

Edited by Drs. Juergen Braun and Joachim Sieper, this issue of Rheumatic Disease Clinics comprehensively reviews the state of the art of spondyloarthritis (SpA) diagnosis, prognosis, pathogenesis and genetic insights, and treatment. The worldwide burden of SpA now exceeds that of rheumatoid arthritis. General topics covered include inflammatory back pain, pathophysiology, imaging techniques, and therapeutic strategies.

Literally thousands of papers have been published on nitric oxide over the past ten years. But there is no single monograph available that has previously attempted to summarize the important features of the roles of nitric oxide in inflammation. The voluminous literature regarding the incredible range of chemical and biological effects of nitric oxide and reactive nitrogen oxide species, RNOS, may present a tangle of confusing information to the researcher. This volume brings together experts from nitric oxide and inflammation research and presents a concise up-to-date overview as well as future aspects of this rapidly growing field.